Evaluation of CAR Expression - Protein Solutions

Fluorescence-Labeled Proteins

Key Features

  • Specifically targets pre-labeled antigens with a fluorescent dye
  • Significantly reduces processing time by using direct-labeled proteins
  • Eliminates non-specific reactions of secondary antibodies

FITC-Labeled

  • BCMA
  • CD19
  • CD22
  • GPC3
  • MSLN
  • Protein L

PE-Labeled

  • MSLN

Case Study

Evaluation of Anti-CD19 CAR Expression with FITC-labeled CD19

293 cells were transfected with anti-CD19-scFv and RFP tag. 2e5 of the cells were stained with B. FITC-Labeled Human CD19 (20-291) (Cat. No. CD9-HF2H2, 10 µg/ml) and C. FITC-labeled protein control. A. Non-transfected 293 cells and C. FITC-labeled protein control were used as negative control. RFP was used to evaluate CAR (anti-CD19-scFv) expression and FITC was used to evaluate the binding activity of FITC-labeled Human CD19 (20-291) (Cat. No. CD9-HF2H2).

293 cells were transfected with anti-CD19-scFv and RFP tag. 2e5 of the cells were stained with B. FITC-Labeled Human CD19 (20-291) (Cat. No. CD9-HF2H2, 10 µg/ml) and C. FITC-labeled protein control. A. Non-transfected 293 cells and C. FITC-labeled protein control were used as negative control. RFP was used to evaluate CAR (anti-CD19-scFv) expression and FITC was used to evaluate the binding activity of FITC-labeled Human CD19 (20-291) (Cat. No. CD9-HF2H2).

Biotinylated Proteins

Key Features

  • Antigens pre-labeled with biotin can be specifically targeted and detected by labeled streptavidin, which is the biotin-avidin complex.
  • Molecules labeled with streptavidin fluorochromes can bind biotinylated proteins with high affinity and specificity. This amplifies the signal and improves the overall sensitivity and specificity of the detection process.
  • BCMA
  • CD19
  • CD22
  • CD30
  • CD33
  • CD38
  • CD70
  • EGFR
  • EGFRVIII
  • EpCAM
  • FOLR1
  • GPC3
  • HER2
  • HGFR
  • MSLN
  • ROR1
  • Protein L

Case Study

Evaluation of Anti-BCMA CAR Expression with Biotinylated BCMA

Human T cells were transfected with anti-BCMA CAR and cultured for 3 days. Three days post-transfection, 1e6 cells were first incubated with 50 µl biotinylated human BCMA protein (Cat. No. BC7-H82F0, 8 µg/ml), washed and then stained with PE Streptavidin and analyzed by flow cytometry. (Data are kindly provided by PREGENE Biopharma)

Human T cells were transfected with anti-BCMA CAR and cultured for 3 days. Three days post-transfection, 1e6 cells were first incubated with 50 µl biotinylated human BCMA protein (Cat. No. BC7-H82F0, 8 µg/ml), washed and then stained with PE Streptavidin and analyzed by flow cytometry. (Data are kindly provided by PREGENE Biopharma)

Unconjugated Proteins

Key Features

  • Specifically targets antigens that have been designed to carry a specific tag
  • Antigens are detected using a secondary antibody, which is also referred to as an anti-epitope tag antibody, that has been labeled with a fluorophore
  • Non-specific reactions of a secondary antibody may occur
  • BCMA
  • CD19
  • CD123
  • CD138
  • CD22
  • CD30
  • CD33
  • CD38
  • CD70
  • CAIX
  • EGFR
  • EGFRVIII
  • EpCAM
  • FOLR1
  • GPC3
  • FOLR1
  • HER2
  • HGFR
  • IL13RA2
  • MSLN
  • MUC1
  • ROR1

Case Study

Evaluation of Anti-CD19 CAR Expression with Fc-fusion CD19

293 cells were transfected with FMC63-scFv and RFP tag. 2e5 of the cells were first stained with B. Human CD19 (20-291) Protein, Fc Tag, low endotoxin (Super affinity) (Cat. No. CD9-H5251 , 3 µg/ml) and C. Human Fc Tag Protein Control, followed by FITC-conjugated Anti-human IgG Fc Antibody. A. Non-transfected 293 cells and C. Human Fc Tag Protein Control were used as negative control. RFP was used to evaluate CAR (anti-CD19-scFv) expression and FITC was used to evaluate the binding activity of Human CD19 (20-291) Protein, Fc Tag, low endotoxin (Super affinity) (Cat. No. CD9-H5251).

293 cells were transfected with FMC63-scFv and RFP tag. 2e5 of the cells were first stained with B. Human CD19 (20-291) Protein, Fc Tag, low endotoxin (Super affinity) (Cat. No. CD9-H5251 , 3 µg/ml) and C. Human Fc Tag Protein Control, followed by FITC-conjugated Anti-human IgG Fc Antibody. A. Non-transfected 293 cells and C. Human Fc Tag Protein Control were used as negative control. RFP was used to evaluate CAR (anti-CD19-scFv) expression and FITC was used to evaluate the binding activity of Human CD19 (20-291) Protein, Fc Tag, low endotoxin (Super affinity) (Cat. No. CD9-H5251).